NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Receives FDA IND Approval for Phase 2 OASIS Trial of TNX-102 SL in Acute Trauma Patients
Tonix Pharmaceuticals Holding (NASDAQ: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that it has received approval from the U.S. Food and Drug Administration (“FDA”) for the Investigational New Drug (“IND”) application for the investigator-initiated OASIS trial. The OASIS trial is a Phase 2 trial to evaluate TNX-102 SL in reducing the severity of acute stress reaction (“ASR”) and the frequency of acute stress disorder (“ASD”) and posttraumatic stress disorder (“PTSD”). The trial will enroll approximately 180 acute trauma patients following motor vehicle collisions. It is sponsored by The University of North Carolina…







